This makes targeted taxation a promising lever to help slow antimicrobial resistance—though always with care to protect patients who truly need broad-spectrum coverage.
Open access 👉 doi.org/10.1016/j.ij...

Using UK sales data, we show that taxes on all antibiotics cut broad-spectrum use only modestly—& at high cost. But targeted taxes on AMR-promoting broad-spectrum drugs cut use much more, shift demand toward narrow-spectrum, & cause minimal welfare loss.
#HealthEconomics